ترايدر
عضو نشط
- التسجيل
- 14 مارس 2004
- المشاركات
- 321
شركة وتقرير
CLRI
4.30$Last Trade
New FDA regulations will make Clearant (CLRI) shareholders rich
At literally any moment, the U.S. Food and Drug Administration will announce mandatory enforcement of its GTP regulations -- Then YOUR CLRI share-value will go ballistic
Buy CLRI now up to $5 before it suddenly shoots well above $25 - and keeps going!The all-powerful U.S. Food & Drug Administration (FDA) has issued the regulations on sterilized tissue that gives Clearant control of the multi-$Billion transplant industry:
1. Now, the transplant of ligaments, tendons, and bones must adhere to the FDA’s Good Tissue Practice (GTP) regulations to qualify as sterile procedures.
2. Now, every doctor, hospital, and insurance company must ensure that they meet these FDA regulations to avoid devastating lawsuits.
3. NOW, Clearant, Inc. (CLRI) is the only biotech company I’ve found to have the proven and proprietary technology to ensure that transplanted human tissues are safely sterile à VAST FORTUNES will be created for early CLRI shareholders.
The company’s Clearant Process® will ultimately dominate the entire transplant and vaccine industries because Clearant’s proprietary technology can prevent more than just bacterial and viral infections – it arguably can stop the transfer of hepatitis and numerous other illnesses spread through blood.
The FDA Has Spoken – Now, Clearant Shareholders Should Get Ready to Get Rich!
Although the Food & Drug Administration’s mission statement does not include making stock recommendations, billions of dollars of investor wealth have been created as a result of fortunate companies gaining FDA favor and approval.
Every day it seems an FDA announcement is driving one particular stock into the stratosphere and making the company’s shareholders into instant millionaires. Isn’t it time YOU finally bought the right stock BEFORE the big announcement? I’m going to show you how: Buy Clearant, Inc. (CLRI) right now.
My near-term projection: At any moment, the FDA will announce the end of its grace-period for GTP compliance; CLRI shares will go through the roof as Clearant’s proprietary stronghold on the tissue sterilization industry is revealed to Wall Street and the investment crowd.
YET, instead of selling into the first wave of frenzied buying, I will be guiding you—my fellow Contrarians—to the next advantageous “buy window” as we increase our CLRI positions in pursuit of a truly MONUMENTAL shareholder win.
Start accumulating your strategic CLRI position now at current price levels up to my initial buy ceiling of $5.
The U.S. FDA:
A Powerful Ally in Our Quest for Immense Clearant Profits
investing, my track record of uncovering behemoth profit stocks is nothing short of Legendary. And now, Clearant is the NEXT company to join my long list of Hall of Fame Picks.
As mentioned, Clearant is the only company I’ve found that meets the FDA’s new strict guidelines on sterilized human tissue for transplant. This is the catalyst that will drive your CLRI share-value multiples higher in the very near-term.
As you know, the biotechnology sector’s technical landscape can be quite treacherous to navigate from an investment standpoint. Yet the sub-sector in which Clearant stands to dominate for years is perfectly simple:
GTP, or Good Tissue Practice, means just that: The FDA now demands the use of “Good Tissue,” or, in layman’s terms – human tissues, ligaments, etc., that are guaranteed to be stripped clean of any and all infectious or communicable disease prior to transplant.
To quote directly from the U.S. Food & Drug Administration’s website : FDA is finalizing its proposed requirements for current good tissue practice for establishments that manufacture human cell, tissue, and cellular and tissue-based products (HCT/Ps). FDA believes that, together with establishment registration, HCT/P listing, donor screening and donor testing requirements, requirements for current good tissue practice will increase the safety of HCT/Ps, and public confidence in their safety, by preventing the introduction, transmission and spread of communicable disease. The Agency’s actions are intended to improve protection of the public health while minimizing regulatory burden.
The requirements aim to prevent the introduction, transmission, and spread of communicable diseases by HCT/Ps, by reducing the risk that the HCT/Ps contain communicable disease agents (e.g., viruses, bacteria, fungi, parasites, and transmissible spongiform encephalopathy agents), and by preventing contamination during manufacturing.
CLRI’s Clearant Process® will soon be making headlines across the biotech sector as the only sterilization method that meets the FDA’s tough new GTP standards. As a select recipient of my unparalleled Contrarian wisdom, you now have this knowledge in-hand well before Wall Street and the investing masses. Use it to your profitable advantage by immediately securing an early position in this future biotechnology leader.
“Profitable” Timeline: The U.S. FDA, upon realization of the growing concern over the safety of transplanted human tissue, stepped in late last year to regulate the industry from a “consumer-safety” standpoint. Now, the FDA’s Good Tissue Practice (GTP) mandate is the Law of the Land.As the FDA’s grace-period comes to a screeching halt, the company’s Clearant Process® will be elevated to the precipice of compliance as the ONLY logical choice in the sterilization of human tissue.
This is as clear-cut as it gets: As a licensed health provider, which would you choose; human tissue that may or may not pass the FDA’s new GTP guidelines and thereby risk potentially devastating litigation — or human tissue that has been declared as “officially sterile” by way of the company’s Clearant Process®? I cannot imagine any licensed provider choosing the former.
Translation: Buy shares of Clearant (CLRI – OTCBB) Now!
CLRI
4.30$Last Trade
New FDA regulations will make Clearant (CLRI) shareholders rich
At literally any moment, the U.S. Food and Drug Administration will announce mandatory enforcement of its GTP regulations -- Then YOUR CLRI share-value will go ballistic
Buy CLRI now up to $5 before it suddenly shoots well above $25 - and keeps going!The all-powerful U.S. Food & Drug Administration (FDA) has issued the regulations on sterilized tissue that gives Clearant control of the multi-$Billion transplant industry:
1. Now, the transplant of ligaments, tendons, and bones must adhere to the FDA’s Good Tissue Practice (GTP) regulations to qualify as sterile procedures.
2. Now, every doctor, hospital, and insurance company must ensure that they meet these FDA regulations to avoid devastating lawsuits.
3. NOW, Clearant, Inc. (CLRI) is the only biotech company I’ve found to have the proven and proprietary technology to ensure that transplanted human tissues are safely sterile à VAST FORTUNES will be created for early CLRI shareholders.
The company’s Clearant Process® will ultimately dominate the entire transplant and vaccine industries because Clearant’s proprietary technology can prevent more than just bacterial and viral infections – it arguably can stop the transfer of hepatitis and numerous other illnesses spread through blood.
The FDA Has Spoken – Now, Clearant Shareholders Should Get Ready to Get Rich!
Although the Food & Drug Administration’s mission statement does not include making stock recommendations, billions of dollars of investor wealth have been created as a result of fortunate companies gaining FDA favor and approval.
Every day it seems an FDA announcement is driving one particular stock into the stratosphere and making the company’s shareholders into instant millionaires. Isn’t it time YOU finally bought the right stock BEFORE the big announcement? I’m going to show you how: Buy Clearant, Inc. (CLRI) right now.
My near-term projection: At any moment, the FDA will announce the end of its grace-period for GTP compliance; CLRI shares will go through the roof as Clearant’s proprietary stronghold on the tissue sterilization industry is revealed to Wall Street and the investment crowd.
YET, instead of selling into the first wave of frenzied buying, I will be guiding you—my fellow Contrarians—to the next advantageous “buy window” as we increase our CLRI positions in pursuit of a truly MONUMENTAL shareholder win.
Start accumulating your strategic CLRI position now at current price levels up to my initial buy ceiling of $5.
The U.S. FDA:
A Powerful Ally in Our Quest for Immense Clearant Profits
investing, my track record of uncovering behemoth profit stocks is nothing short of Legendary. And now, Clearant is the NEXT company to join my long list of Hall of Fame Picks.
As mentioned, Clearant is the only company I’ve found that meets the FDA’s new strict guidelines on sterilized human tissue for transplant. This is the catalyst that will drive your CLRI share-value multiples higher in the very near-term.
As you know, the biotechnology sector’s technical landscape can be quite treacherous to navigate from an investment standpoint. Yet the sub-sector in which Clearant stands to dominate for years is perfectly simple:
GTP, or Good Tissue Practice, means just that: The FDA now demands the use of “Good Tissue,” or, in layman’s terms – human tissues, ligaments, etc., that are guaranteed to be stripped clean of any and all infectious or communicable disease prior to transplant.
To quote directly from the U.S. Food & Drug Administration’s website : FDA is finalizing its proposed requirements for current good tissue practice for establishments that manufacture human cell, tissue, and cellular and tissue-based products (HCT/Ps). FDA believes that, together with establishment registration, HCT/P listing, donor screening and donor testing requirements, requirements for current good tissue practice will increase the safety of HCT/Ps, and public confidence in their safety, by preventing the introduction, transmission and spread of communicable disease. The Agency’s actions are intended to improve protection of the public health while minimizing regulatory burden.
The requirements aim to prevent the introduction, transmission, and spread of communicable diseases by HCT/Ps, by reducing the risk that the HCT/Ps contain communicable disease agents (e.g., viruses, bacteria, fungi, parasites, and transmissible spongiform encephalopathy agents), and by preventing contamination during manufacturing.
CLRI’s Clearant Process® will soon be making headlines across the biotech sector as the only sterilization method that meets the FDA’s tough new GTP standards. As a select recipient of my unparalleled Contrarian wisdom, you now have this knowledge in-hand well before Wall Street and the investing masses. Use it to your profitable advantage by immediately securing an early position in this future biotechnology leader.
“Profitable” Timeline: The U.S. FDA, upon realization of the growing concern over the safety of transplanted human tissue, stepped in late last year to regulate the industry from a “consumer-safety” standpoint. Now, the FDA’s Good Tissue Practice (GTP) mandate is the Law of the Land.As the FDA’s grace-period comes to a screeching halt, the company’s Clearant Process® will be elevated to the precipice of compliance as the ONLY logical choice in the sterilization of human tissue.
This is as clear-cut as it gets: As a licensed health provider, which would you choose; human tissue that may or may not pass the FDA’s new GTP guidelines and thereby risk potentially devastating litigation — or human tissue that has been declared as “officially sterile” by way of the company’s Clearant Process®? I cannot imagine any licensed provider choosing the former.
Translation: Buy shares of Clearant (CLRI – OTCBB) Now!
